Every Journey Starts With a Step
We started ours in 1989 when our founders, Randy W. Hamilton and Lorin K. Johnson, PhD, realized the need for more effective gastrointestinal solutions. Since then, Salix hasn’t stopped moving forward.
1989
- Salix Pharmaceuticals is founded in Sunnyvale, California
1990
- COLAZAL® (balsalazide disodium) is licensed
1996
- XIFAXAN® (rifaximin) is licensed
2000
- Operations move to Raleigh, North Carolina
- COLAZAL® (balsalazide disodium) receives FDA approval
2004
- XIFAXAN® (rifaximin) 200 mg receives FDA approval for treatment of non-invasive traveler's diarrhea
2006
- MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) receives FDA approval
2008
- APRISO® (mesalamine granules) receives FDA approval
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for opioid-induced constipation (OIC) in adults with advanced illness when other medicines for constipation have not worked well enough
2009
- OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) receives FDA approval
2010
- XIFAXAN® (rifaximin) 550 mg receives FDA approval for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults
2013
- UCERIS® (budesonide) extended-release tablets receives FDA approval
- GIAZO® (mesalamine) receives FDA approval
2014
- Salix acquires Santarus
- RELISTOR® (methylnaltrexone bromide) subcutaneous injection receives FDA approval for OIC in adults with chronic non-cancer pain
2015
- UCERIS® (budesonide) rectal foam receives FDA approval
- XIFAXAN® (rifaximin) 550 mg receives FDA approval for irritable bowel syndrome with diarrhea (IBS-D) in adults
- Valeant acquires Salix
- Operations begin moving to Bridgewater, New Jersey, our current location
2016
- Salix launches RELISTOR® (methylnaltrexone bromide) tablets
2017
- Salix scales up sales force by nearly 40 percent
2018
- Valeant changes name to Bausch Health
- Salix launches PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution)
- Salix launches LUCEMYRA (lofexidine) tablets 1.18mg
2019
- Salix celebrates three decades of GI solutions
- Bausch Health completes acquisition of certain assets of Synergy Pharmaceuticals, including Trulance (plecanatide)